(Q37452843)

20 August 2017

1 reference

title

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors (English)

1 reference

20 August 2017

0 references

Kevin Kelly

1

1 reference

20 August 2017

Ronan Swords

2

1 reference

20 August 2017

Devalingam Mahalingam

3

1 reference

20 August 2017

Swaminathan Padmanabhan

4

1 reference

20 August 2017

Francis J Giles

5

1 reference

20 August 2017

21 April 2009

1 reference

20 August 2017

1 reference

20 August 2017

4

1 reference

20 August 2017

2

1 reference

20 August 2017

99-105

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-009-0110-4

20 August 2017

0 references

cites work

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11523-009-0110-4

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

12 December 2020

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

1 reference

12 December 2020

Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.

1 reference

12 December 2020

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

12 December 2020

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

1 reference

12 December 2020

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

1 reference

12 December 2020

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

12 December 2020

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

12 December 2020

Functions of Bruton's tyrosine kinase in mast and B cells

1 reference

12 December 2020

Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis

1 reference

12 December 2020

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

12 December 2020

Tec family kinases in T lymphocyte development and function

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo

1 reference

12 December 2020

A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer

1 reference

12 December 2020

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

1 reference

12 December 2020

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

12 December 2020

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

12 December 2020

Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib

1 reference

12 December 2020

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

1 reference

12 December 2020

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

1 reference

12 December 2020

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

12 December 2020

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

12 December 2020

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

12 December 2020

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

1 reference

12 December 2020

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

12 December 2020

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

1 reference

12 December 2020

Mechanism of action and in vivo role of platelet-derived growth factor

1 reference

12 December 2020

Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site.

1 reference

12 December 2020

Current and emerging treatment options in chronic myeloid leukemia

1 reference

12 December 2020

Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia

1 reference

12 December 2020

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

12 December 2020

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

12 December 2020

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia

1 reference

12 December 2020

SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice

1 reference

12 December 2020

Expression of discoidin domain receptor 1 tyrosine kinase on the human bronchial epithelium.

1 reference

12 December 2020

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

1 reference

12 December 2020

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

1 reference

12 December 2020

10.1007/S11523-009-0110-4

Identifiers

DOI

1 reference

release_ahxyxsvdsbcbhci5mjwjzkkhvi

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ahxyxsvdsbcbhci5mjwjzkkhvi

24 November 2022

mapped directly with Wikidata item

1 reference